Induction of secretory immunity and memory at mucosal surfaces (Q36709727)

15 August 2017

1 reference

title

Induction of secretory immunity and memory at mucosal surfaces (English)

1 reference

15 August 2017

Per Brandtzaeg

1

1 reference

PubMed ID

17227687

15 August 2017

language of work or name

English

0 references

publication date

15 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

25

1 reference

15 August 2017

5467-5484

1 reference

15 August 2017

30

1 reference

Immunization without needles

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Can needle-free administration of vaccines become the norm in global immunization?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Role of secretory antibodies in the defence against infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Let's go mucosal: communication on slippery ground

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The B-cell system of human mucosae and exocrine glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

How many child deaths can we prevent this year?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Global health improvement and WHO: shaping the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunoglobulin A supplementation abrogates bacterial translocation and preserves the architecture of the intestinal epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human milk feedings and infection among very low birth weight infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Breast feeding and acute lower respiratory infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

How breast milk protects newborns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Increasing breastfeeding rates to reduce infant illness at the community level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mumps IgA antibodies are not absorbed from human milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The ontogeny of serum IgA in the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Molecular analysis of commensal host-microbial relationships in the intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Regional specialization in the mucosal immune system: what happens in the microcompartments?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Regional specialization in the mucosal immune system: primed cells do not always home along the same track

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Bronchus-associated lymphoid tissue (BALT) and larynx-associated lymphoid tissue (LALT) are found at different frequencies in children, adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Collaboration of epithelial cells with organized mucosal lymphoid tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

How do DCs interact with intestinal antigens?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The intestinal epithelial cell: immunological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

M cell pockets of human Peyer's patches are specialized extensions of germinal centers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

From B to A the mucosal way

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intestinal IgA synthesis: regulation of front-line body defences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Chemokines and the tissue-specific migration of lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intestinal bacteria and development of the B-lymphocyte repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Textbook germinal centers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

IgA production without mu or delta chain expression in developing B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

B cell receptor signal strength determines B cell fate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Cutting edge: innate immunity conferred by B cells is regulated by caspase-8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Control of B-cell responses by Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Translating innate immunity into immunological memory: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Toll-like receptor 2-mediated human B cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Antibody-enhanced pneumococcal adherence requires IgA1 protease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Retinoic acid imprints gut-homing specificity on T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

T cell control of the gut IgA response against commensal bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Timing, localization, and persistence of colonization by segmented filamentous bacteria in the neonatal mouse gut depend on immune status of mothers and pups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

IgVH gene analysis suggests that peritoneal B cells do not contribute to the gut immune system in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Hypermutation, diversity and dissemination of human intestinal lamina propria plasma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human IgA- and IgM-secreting intestinal plasma cells carry heavily mutated VH region genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Characteristics of IgVH genes used by human intestinal plasma cells from childhood.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Characteristics of human IgA and IgM genes used by plasma cells in the salivary gland resemble those used in duodenum but not those used in the spleen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

IgA and IgM V(H) repertoires in human colon: evidence for clonally expanded B cells that are widely disseminated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Sequence analysis of human IgVH genes indicates that ileal lamina propria plasma cells are derived from Peyer's patches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Presence of J chain in human immunocytes containing various immunoglobulin classes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Role of J chain in secretory immunoglobulin formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mechanism of IL-4-mediated up-regulation of the polymeric Ig receptor: role of STAT6 in cell type-specific delayed transcriptional response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

A novel NF-kappa B/Rel site in intron 1 cooperates with proximal promoter elements to mediate TNF-alpha-induced transcription of the human polymeric Ig receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Transcriptional regulation of the mucosal IgA system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Vitamin A is required for regulation of polymeric immunoglobulin receptor (pIgR) expression by interleukin-4 and interferon-gamma in a human intestinal epithelial cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Innate defenses of the intestinal epithelial barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunoglobulins in feces from infants fed human or bovine milk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

In vivo IgA coating of anaerobic bacteria in human faeces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Development of dome epithelium in gut-associated lymphoid tissues: association of IgA with M cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Secretory IgA possesses intrinsic modulatory properties stimulating mucosal and systemic immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The secretory immunoglobulin system: regulation and biological significance. Focusing on human mammary glands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human polymeric IgA is superior to IgG and single-chain Fv of the same monoclonal specificity to inhibit urease activity associated with Helicobacter pylori.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human secretory immunoglobulin A may contribute to biofilm formation in the gut.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Novel mucosal anti-microbial functions interfering with the plasmid-mediated virulence determinants of adherence and drug resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

A three-tiered view of the role of IgA in mucosal defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

A mucosal IgA-mediated excretory immune system in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Free secretory component and lactoferrin of human milk inhibit the adhesion of enterotoxigenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Binding of Clostridium difficile toxin A to human milk secretory component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Expression and modulation of the human immunoglobulin A Fc receptor (CD89) and the FcR gamma chain on myeloid cells in blood and tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

IL-8 released constitutively by primary bronchial epithelial cells in culture forms an inactive complex with secretory component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosal penetrability enhanced by serum-derived antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunoglobulin secretion in the airways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Rotavirus infection in infants as protection against subsequent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Studies in experimental immunology of influenza. IX. The mode of action of pathotopic adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosal B cell deficiency in IgA-/- mice abrogates the development of allergic lung inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in murine nasotracheal anti-influenza immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Formation of secretory and circulating antibodies after immunization with live and inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The effect of antibody on the intestinal absorption of macromolecules and on intestinal permeability in adult mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Innate secretory antibodies protect against natural Salmonella typhimurium infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Recent advances in mucosal vaccines and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Adenoviral vectors for mucosal vaccination against infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The future of rotavirus vaccines: a major setback leads to new opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

The potential of plant virus vectors for vaccine production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Opportunities for recombinant antigen and antibody expression in transgenic plants--technology assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

High prevalence of influenza specific antibody secreting cells in nasal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Parenteral influenza vaccination induces a rapid systemic and local immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Influenza vaccination for healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immune response to Mycoplasma pulmonis in nasal mucosa is modulated by the normal microbiota

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Intranasal delivery of vaccines against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Diversity of antibody-mediated immunity at the mucosal barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

7 January 2021

Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

7 January 2021

Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

7 January 2021

Adsorption of immunolgobulin A onto oral bacteria in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.001

7 January 2021

10.1016/J.VACCINE.2006.12.001

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17227687